Skip to content
Screener

Reported November 10, 2026 · Before market open

Revenue$12.9MMiss by $1.1M
EPS-$0.15Miss by $0.02
Revenue estimate$14.0M
EPS estimate-$0.13
“The third quarter marked an important period of growth and expansion for TriSalus – we drove double-digit year-over-year growth and received FDA clearance for TriNav Advance, which enables Pressure-Enabled Drug Delivery to small distal vessels through the microcatheter of the physician's choice. This clearance allows us to address the full range of vessels encountered in liver embolization procedures going forward. Looking ahead, we believe we are well positioned for 2027. We more than doubled our commercial footprint over the first half of the year, and although our team productivity has ramped slightly slower than anticipated, our representatives continue to educate and drive further TriNav utilization as they build and strengthen relationships with interventional radiologists. Combined with the launch of TriNav Advance, expanded access to office-based labs through the new G-code, and continued cost discipline, we believe we have laid the foundation for continued growth in 2027 and beyond.”
Mary Szela

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$12.9M+11.3%
Gross profit$11.1M+14.9%
Operating income-$7.7M+14.5%
Net income-$8.9M+18.1%
EPS (diluted)-$0.15+84.4%

Balance sheet

See full
Cash & equivalents$41.1M+78.2%
Total debt$32.4M-1.2%
Total equity$680.0K+103%
Total assets$57.6M+57.9%

Cash flow

See full
Operating cash flow-$5.3M-42.2%
CapEx$90.0K-58.3%
Free cash flow-$5.4M-36.7%

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$198.27M-0.6%
Enterprise value$189.58M-9.4%
P/S4.3×-0.7×

Profitability

See full
Gross margin86.5%+2.4pp
Operating margin-63%-10.1pp
Net margin-56.6%-16.9pp
FCF margin-53.3%-1.7pp

Returns & leverage

See full
Debt / equity47.6×—
Current ratio4.2×+1.2×

FAQ

When did TriSalus Life Sciences, Inc. report Q3 2026 earnings?
TriSalus Life Sciences, Inc. (TLSI) reported Q3 2026 earnings on November 10, 2026 before market open.
What were TriSalus Life Sciences, Inc.'s Q3 2026 revenue and EPS?
TriSalus Life Sciences, Inc. reported revenue of $12.9M and eps of $-0.15 for Q3 2026.
Did TriSalus Life Sciences, Inc. beat estimates in Q3 2026?
Revenue missed the consensus estimate of $14.0M by $1.1M. EPS missed the consensus estimate of $-0.13 by $0.02.
How did TriSalus Life Sciences, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 11.3% from $11.6M a year earlier and eps grew 84.4% from $-0.96.
Where can I find TriSalus Life Sciences, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-072513) and the 10-Q periodic report (0001628280-26-072515) directly on SEC EDGAR. The filing index links above go to sec.gov.